{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:01:49Z","timestamp":1784548909353,"version":"3.55.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,7,17]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Introduction: Antibody-based immunotoxins are a promising novel therapeutic approach aimed at targeted cancer therapy, utilizing the target specificity of antibody\nfragments attached to a potent cytotoxic molecule. Oportuzumab monatox, an EpCAM-specific immunotoxin, has shown clinical activity in Non-Muscle-Invasive Bladder Cancer (NMIBC) but is limited by its high immunogenicity. To address this limitation, we developed a novel construct comprising the 4D5mocB antibody fragment fused\nto a truncated, deimmunized Pseudomonas aeruginosa exotoxin A.\n\nMethods: Various bioinformatics methods were employed to assess physicochemical\ncharacteristics and analyze structural stability using Molecular Dynamics (MD) simulations. The predicted epitope content for B cells and T cells, as well as the binding affinity for the EpCAM receptor, were also evaluated and compared with that of the parental\nimmunotoxin.\n\nResults: Molecular dynamics analysis showed that the 4D5mocB-PE24 immunotoxin\nrapidly stabilized within 10 ns, maintaining RMSD values of 0.5-0.7 nm, whereas the\nPE40-based complex exceeded 2.0 nm after 22 ns. Moreover, computational modeling\nof the truncation and deimmunization process reduced the predicted number of B- and\nT-cell epitopes by 56% and 43%, respectively, and markedly decreased MHC class II\nbinding.\n\nDiscussion: These findings demonstrate that epitope deletion and rational mutagenesis\nsubstantially reduce predicted immunogenicity while preserving high target-binding\naffinity; however, these findings will require experimental validation.\n\nConclusion: This study identifies 4D5mocB-PE24 as a promising anti-EpCAM immunotoxin candidate with reduced immunogenicity, supporting further preclinical and clinical\nevaluation for EpCAM-positive cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673449093260701060245","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:06:25Z","timestamp":1784545585000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Silico Design and Structural Characterization of 4D5mocB-PE24:\nA Novel Immunotoxin for EpCAM-Targeted Cancer Therapy"],"prefix":"10.2174","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9749-9641","authenticated-orcid":true,"given":"Fatemeh","family":"Heidari","sequence":"first","affiliation":[{"name":"Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"},{"name":"Student Research Committee, TabrizUniversity of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6087-9147","authenticated-orcid":true,"given":"Safar","family":"Farajnia","sequence":"additional","affiliation":[{"name":"Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"},{"name":"Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7209-2288","authenticated-orcid":true,"given":"Reza","family":"Salahlou","sequence":"additional","affiliation":[{"name":"Student Research Committee, TabrizUniversity of Medical Sciences, Tabriz, Iran"},{"name":"Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4287-6698","authenticated-orcid":true,"given":"Hossein","family":"Babaei","sequence":"additional","affiliation":[{"name":"Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"},{"name":"Pharmacology and Toxicology Department, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-8028","authenticated-orcid":true,"given":"Leila","family":"Rahbarnia","sequence":"additional","affiliation":[{"name":"Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673449093260701060245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/256338\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673449093260701060245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:06:31Z","timestamp":1784545591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/256338\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673449093260701060245","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}